Related Experiment Videos
[Thalidomide in adult multisystem Langerhans cell histiocytosis: a case report]
Z Alioua1, N Hjira, S Oumakhir
1Service de dermatologie, hôpital militaire d'instruction Mohammed-V, BP 1018, Rabat, Maroc. zalioua@hotmail.com
La Revue De Medecine Interne
|April 25, 2006
Summary
Thalidomide effectively treated multisystem Langerhans cell histiocytosis in an adult patient. This rare condition showed significant improvement in skin and hormonal symptoms with no adverse effects.
Area of Science:
- Dermatology
- Endocrinology
- Oncology
Background:
- Adult multisystem Langerhans cell histiocytosis (aLCH) is a rare disorder with varied treatment options.
- Investigating novel therapeutic agents for aLCH is crucial due to its challenging nature.
- This study evaluated thalidomide's efficacy in a specific case of adult multisystem Langerhans cell histiocytosis.
Observation:
- A 43-year-old female presented with multifocal chronic aLCH affecting cutaneous, oral, perianal, mastoid, and hypothalamic regions.
- The patient experienced severe ulcers, central diabetes insipidus, and amenorrhea.
- Treatment involved thalidomide 200 mg/day following a neurological assessment.
Findings:
- Thalidomide administration resulted in a rapid and complete resolution of skin lesions.
- A significant improvement in central diabetes insipidus was observed.
- The patient maintained a 1-year remission without any reported adverse effects from thalidomide.
Implications:
- Thalidomide demonstrates potential as an effective treatment for adult multisystem Langerhans cell histiocytosis.
- The findings suggest thalidomide's utility in managing both the mucocutaneous and endocrine manifestations of aLCH.
- This case highlights thalidomide as a viable therapeutic option for rare and difficult-to-treat aLCH cases.
